Goa facility FDA classification pending
Goa facility received six 483 observations after U.S. FDA reinspection; official classification awaited, which could impact product approvals.
high · management_commentaryCipla Ltd — Q1 FY25
Cipla delivered a strong Q1 FY25 with revenue of INR 6,694 crore (+7% YoY) and EBITDA margin of 25.6% (+154 bps YoY), driven by a favorable product mix and calibrated pricing.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Potential price erosion from new Albuterol entrants
New competitors entering the Albuterol inhalation market could lead to price erosion and market share loss, though management notes market expansion.
medium · analyst_questionLanreotide supply constraints limiting ramp-up
Supply from partner is constrained, leading to gradual ramp-up for Lanreotide generic; capacity limitations may cap near-term revenue.
medium · analyst_questionTrade generic transition disruption
Transition to new distribution model caused temporary softness in trade generic business; recovery expected but execution risk remains.
low · management_commentary